ASPIC

A investigação e a inovação em cancro na América Latina são limitadas devido a recursos académicos inadequados e a investigação de translação depende quase totalmente de financiamento público. A complexidade regulatória e os prazos de resposta excessivos colocam colocam em causa a melhoria potencial na participação em estudos internacionais.

A investigação e a inovação em cancro na América Latina são limitadas devido a recursos académicos inadequados e a investigação de translação depende quase totalmente de financiamento público. A complexidade regulatória e os prazos de resposta excessivos colocam colocam em causa a melhoria potencial na participação em estudos internacionais.

Seville Exhibition and Conference Centre, Seville, Spain

20-23 June 2022

See more informations here: https://www.eacr2022.org/?utm_source=eacrnews&utm_medium=email&utm_campaign=eacrnews

Seville Exhibition and Conference Centre, Seville, Spain

20-23 June 2022

See more informations here: https://www.eacr2022.org/?utm_source=eacrnews&utm_medium=email&utm_campaign=eacrnews

Virtual event, Worldwide

22-23 February, 2022

See more informations here: https://www.eacr.org/conference/structuralmicroenv2022virtual/index?utm_source=eacrnews&utm_medium=email&utm_campaign=vSM22&utm_content=

Virtual Event, Worldwide

07-08 December, 2021

See more informations here: https://www.eacr.org/conference/astrazeneca2021virtual?utm_source=eacrnews&utm_medium=email&utm_campaign=vAZ21

Virtual Event, Worldwide

07-08 December, 2021

See more informations here: https://www.eacr.org/conference/astrazeneca2021virtual?utm_source=eacrnews&utm_medium=email&utm_campaign=vAZ21

On-line event

25-26 January, 2022

See more informations here: https://www.eacr.org/conference/seedandsoil2022/index

On-line event

25-26 January, 2022

See more informations here: https://www.eacr.org/conference/seedandsoil2022/index

Over 70% of breast cancers (BC) are estrogen receptor-positive (ER+). The Notch ligand Delta-like 1 (DLL1) is a key player in ER+ BCs development and aggressiveness and its overexpression are associated with poor prognosis. In this study, Portuguese researchers developed a novel anti-DLL1 antibody that inhibited tumor growth and liver metastases in a xenograft mouse model. The data suggests that anti-DLL1 immunotherapy can be a promising strategy for ER+ BC treatment.

Authors and Affiliations: